Syngene International has extended its strategic collaboration with Bristol Myers Squibb (BMS) through 2035, broadening the scope of services across the drug development lifecycle. The long-term agreement covers discovery sciences, translational research, pharmaceutical development and manufacturing, clinical trials, and data and information technology services, enabling seamless progression from research to commercialization.

Peter Bains, managing director and CEO of Syngene International, said: “Our collaboration with Bristol Myers Squibb, which now spans more than 25 years, is anchored in scientific excellence, operational reliability, and a shared commitment to advancing innovative therapies. Extending this partnership through 2035 allows us to plan for new capabilities and infrastructure over the next decade. Taking a long-term perspective is a key feature of our partnership which adds strategic value to both companies. We look forward to supporting BMS with their next wave of discovery, development, and manufacturing programs that have the potential to improve patient outcomes worldwide.”

Payal Sheth, senior vice president, therapeutic discovery sciences at Bristol Myers Squibb, added: “At Bristol Myers Squibb, everything we do begins with patients. We greatly value our long-standing partnership with Syngene, which has been instrumental in advancing our scientific ambitions. This expanded collaboration reflects our commitment to advancing innovative science by integrating research, development, and manufacturing capabilities to accelerate the delivery of transformative medicines for patients waiting for new treatment options.”

The collaboration, which began in 1998, led to the creation of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene’s first dedicated R&D facility, commissioned in 2009. The BBRC has grown into a major strategic R&D site for BMS, supporting integrated capabilities across target identification, lead discovery, lead optimisation, pharmaceutical development, molecular and cell biology, protein sciences, assay biology, and clinical biomarkers. Around 700 Syngene scientists work at the center as an extension of Bristol Myers Squibb’s global research organization, contributing to discovery, preclinical development, and patent filings across cardiovascular, fibrosis, immunology, and oncology programs.

Over the years, BBRC has accelerated the progression of novel compounds from early discovery to first-in-human studies, helping reduce development timelines and overall costs for Bristol Myers Squibb.